摘要
目的通过对非小细胞肺癌(NSCLC)组织中高迁移率族蛋白A2(HMGA2)、肿瘤转移抑制基因(nm23-H1基因)表达及相关研究,探讨其与临床特征之间的关系。方法对40例NSCLC患者经支气管镜钳取的肺癌组织、15例癌旁组织和20例正常组织,应用免疫组织化学法检测3组中HMGA2和nm23-H1的表达水平。结果正常组织中HMGA2和nm23-H1均无表达;HMGA2在癌组织的表达明显高于癌旁组织,而nm23-H1在癌组织的表达明显低于癌旁组织,差异有统计学意义(均P<0.05);在伴有淋巴结转移的NSCLC组织中肿瘤转移抑制基因(nm23-H1基因)表达20.0%(4/20)明显低于在未伴有淋巴结转移的NSCLC组织中表达60.0%(12/20),两者差异具有统计学意义;HMGA2在TNM(Ⅰ+Ⅱ)期NSCLC组织中表达低于在TNM(Ⅲ+Ⅳ)期中的表达,高分化NSCLC中HMGA2的表达低于在低分化NSCLC中的表达(均P<0.05);但nm23-H1在TNM(Ⅰ+Ⅱ)期NSCLC组织中表达高于在TNM(Ⅲ+Ⅳ)期组织中表达,高分化NSCLC组织中nm23-H1的表达高于在低分化NSCLC组织中的表达,差异均具有统计学意义(P<0.05);HMGA2的表达与nm23-H1的表达成负相关(rs=-0.342,P<0.05)。结论 HMGA2和nm23-H1的表达可能与NSCLC的发生、临床进展及预后可能相关。HMGA2和nm23-H1有可能作为NSCLC的早期诊断指标。
Objective To study the expressions of high mobility group A2 （HMGA2） and nm23-H1 in non-small cell lung cancer（NSCLC） and investigate the relationship of HMGA2 and nm23-H1 with clinical features of NSCLC. Methods The expression of HMGAz and nm23-H1 in 40 cases of NSCLC, 15 cases of tissue beside cancer and 20 cases of normal lung tissue were detected by immunohistochemical method. Results Normal lung tissue showed no expression in both indexes. The expressions of HMGA2 in NSCLC were significantly higher than those of the tissue beside cancer（ P d0.05）, but the expressions of nm23-H1 in NSCLC were significantly lower than those of the tissue beside cancer（ P d0.05） ; The expressions of HMGA2 and nm23-H1 in NSCLC patients were correlated with their TNM （ I ＋ II ） stage （all P d0.05）. The expression of HMGAz had negative correlation with the expression of nm23- H1 in NSCLC（ rs=-0. 342, P d0.05）. Conclusion The positive staining of HMGA2 and nm23-H1 are related to carcinogenesis,progression and prognosis of NSCLC. HMGA2 could serve as early diagnostic marker in NSCLC, and detection of both HMGA2 and nm23 H1 can be used to judge the malignant level and prognosis of NSCLC.
出处
《临床荟萃》
CAS
2013年第2期138-140,F0002,共4页
Clinical Focus
基金
甘肃省技术研究与开发专项计划(0912TCYA016)
